Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.77 |
| ▸ | HTR2B | P41595 | 3/20 | 0.77 |
| ▸ | HTR2C | P28335 | 2/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.66 |
| ▸ | DRD3 | P35462 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21115995 | 0.90 | HTR2A (0.63) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 | |
| Nordexfenfluramine SCHEMBL30081489 | 0.87 | HTR2A (1.00) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 | |
| Nordexfenfluramine SCHEMBL895637 | 0.87 | HTR2A (1.00) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 | |
| Nordexfenfluramine SCHEMBL29390405 | 0.87 | HTR2A (1.00) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 | |
| Nordexfenfluramine SCHEMBL30081494 | 0.87 | HTR2A (1.00) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 | |
| Nordexfenfluramine SCHEMBL4668266 | 0.87 | HTR2A (1.00) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 | |
| Nordexfenfluramine SCHEMBL44927 | 0.87 | HTR2A (1.00) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 | |
| SCHEMBL18888417 | 0.87 | HTR2A (0.74) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 | |
| SCHEMBL13719227 | 0.85 | HTR2A (0.58) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 | |
| SCHEMBL5706525 | 0.85 | HTR2A (0.72) | HTR2AHTR2BHTR2CSLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018090-A1 | Processes for the Preparation of Fenfluramine | THE BANK OF NOVA SCOTIA | 2024-01-18 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| WO-2007022638-A1 | BENZODIAZEPINE AND BENZOPIPERAZINE ANALOG INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-03-01 | — | — | WO | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20040097557-A1 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | DUFFY JOSEPH L (US) | 2004-05-20 | — | — | US | disclosed |
| EP-0365678-A1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | HTR2A 673/4885HTR2B 745/4885HTR2C 433/4885 |
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | HTR2A 1167/4885HTR2B 602/4885HTR2C 935/4885 |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | FABP2, APC, SI | HTR2A 3304/4885HTR2B 2817/4885HTR2C 3506/4885 |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | HTR2A 3850/4885HTR2B 3492/4885HTR2C 4218/4885 |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | GPR119, IAPP, GLP1R | HTR2A 35/4885HTR2B 150/4885HTR2C 56/4885 |
| US-20240018090-A1 | Processes for the Preparation of Fenfluramine | PNMT, TPH2, CYP4F3 | HTR2A 34/4885HTR2B 39/4885HTR2C 12/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | HTR2A 1714/4885HTR2B 764/4885HTR2C 634/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | HTR2A 1983/4885HTR2B 1689/4885HTR2C 3013/4885 |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | HTR2A 4853/4885HTR2B 4643/4885HTR2C 4690/4885 |
| US-20040097557-A1 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | GLP1R, GPR119, GCGR | HTR2A 1212/4885HTR2B 854/4885HTR2C 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.